Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease, affecting approximately 30% of adults worldwide. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, affects approximately 12%–14% of middle-aged Americans.
20 weeks of Pegozafermin treatment had beneficial effects on hepatic and metabolic parameters and was well tolerated in subjects with NASH.
Read more about this approved therapy here.